Antibiotics for prophylaxis of spontaneous bacterial peritonitis: systematic review & Bayesian network meta-analysis
Background Various antibiotic regimens are used for primary and secondary prevention of spontaneous bacterial peritonitis (SBP). A systematic review and network meta-analysis to compare various antibiotics regimens for primary and secondary prevention of SBP were done. Methods We did a comprehensive...
Gespeichert in:
| Veröffentlicht in: | Hepatology international 2020-05, Vol.14 (3), p.399-413 |
|---|---|
| Hauptverfasser: | , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 413 |
|---|---|
| container_issue | 3 |
| container_start_page | 399 |
| container_title | Hepatology international |
| container_volume | 14 |
| creator | Soni, Hariom Kumar-M, Praveen Sharma, Vishal Bellam, Balaji L. Mishra, Shubhra Mahendru, Dhruv Mandavdhare, Harshal S. Medhi, Bikash Dutta, Usha Singh, Virendra |
| description | Background
Various antibiotic regimens are used for primary and secondary prevention of spontaneous bacterial peritonitis (SBP). A systematic review and network meta-analysis to compare various antibiotics regimens for primary and secondary prevention of SBP were done.
Methods
We did a comprehensive literature search using various databases (i.e. MEDLINE via Ovid and PubMed, Embase, Cochrane Central Register of Controlled Trials and others) from inception to 26th October 2019 using various keywords. Only randomised studies which evaluated the role of antibiotics in adult cirrhotic patients with ascites for primary or secondary prophylaxis of SBP were included. The primary outcome was occurrence/recurrence of SBP episode and other outcomes assessed were extra-peritoneal infections and reduction in mortality. We did random-effects network meta-analysis using a Bayesian approach, and calculated odds ratios (ORs) and 95% credible intervals (CrI); agents were ranked using rank probabilities.
Results
We found total 1701 records in our systematic database search and out of these 17 randomised trials were found eligible for network meta-analysis. For primary prevention of SBP, the odds ratio (95% CrI) for norfloxacin daily was 0.061 (0.0060, 0.33) and for rifaximin daily was 0.037 (0.00085, 0.87) and norfloxacin and rifaximin alternate month was 0.027 (0.00061, 0.61) when compared to placebo or no comparator. For the secondary prevention of SBP, rifaximin daily had odds of 0.022 (0.00011, 0.73).
Conclusion
Rifaximin is useful for both primary and secondary prevention of SBP whereas norfloxacin daily and alternate norfloxacin and rifaximin are useful for primary prophylaxis. |
| doi_str_mv | 10.1007/s12072-020-10025-1 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2387650444</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2387650444</sourcerecordid><originalsourceid>FETCH-LOGICAL-c441t-4e96d04f0d0d8e5518dc66fe1d3f47f298bc85dcdb593366fb2159936d02d8db3</originalsourceid><addsrcrecordid>eNp9kctu1jAQhS1ERW-8AIvKEhJiE_A9SXdtRQGpEhtYW048AZckTj3-KXl7TFNaiUVXY2u-OePjQ8grzt5xxur3yAWrRcUEq8pd6Io_Iwe8laZiWvHnD2cp98kh4jVjWhtuXpB9KYQxptYHJJ_NOXQh5tAjHWKiS4rLj3V0vwPSOFBc4pzdDHGHtHN9hhTcSJdScpxDDnhKccUMkysKNMGvALf0DT13K2BwM50h38b0k06QXeVmN64Y8JjsDW5EeHlfj8i3yw9fLz5VV18-fr44u6p6pXiuFLTGMzUwz3wDWvPG98YMwL0cVD2Itun6Rvved7qVsnQ6wXVbPHsmfOM7eUTebrrF1M0OMNspYA_juBmyQja10UwpVdDX_6HXcZfKewulyt8yXchCiY3qU0RMMNglhcml1XJm_2Zit0xsycTeZWJ5GTq5l951E_iHkX8hFEBuAJbW_B3S4-4nZP8AaBCY-A</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2402505765</pqid></control><display><type>article</type><title>Antibiotics for prophylaxis of spontaneous bacterial peritonitis: systematic review & Bayesian network meta-analysis</title><source>MEDLINE</source><source>SpringerLink Journals</source><creator>Soni, Hariom ; Kumar-M, Praveen ; Sharma, Vishal ; Bellam, Balaji L. ; Mishra, Shubhra ; Mahendru, Dhruv ; Mandavdhare, Harshal S. ; Medhi, Bikash ; Dutta, Usha ; Singh, Virendra</creator><creatorcontrib>Soni, Hariom ; Kumar-M, Praveen ; Sharma, Vishal ; Bellam, Balaji L. ; Mishra, Shubhra ; Mahendru, Dhruv ; Mandavdhare, Harshal S. ; Medhi, Bikash ; Dutta, Usha ; Singh, Virendra</creatorcontrib><description>Background
Various antibiotic regimens are used for primary and secondary prevention of spontaneous bacterial peritonitis (SBP). A systematic review and network meta-analysis to compare various antibiotics regimens for primary and secondary prevention of SBP were done.
Methods
We did a comprehensive literature search using various databases (i.e. MEDLINE via Ovid and PubMed, Embase, Cochrane Central Register of Controlled Trials and others) from inception to 26th October 2019 using various keywords. Only randomised studies which evaluated the role of antibiotics in adult cirrhotic patients with ascites for primary or secondary prophylaxis of SBP were included. The primary outcome was occurrence/recurrence of SBP episode and other outcomes assessed were extra-peritoneal infections and reduction in mortality. We did random-effects network meta-analysis using a Bayesian approach, and calculated odds ratios (ORs) and 95% credible intervals (CrI); agents were ranked using rank probabilities.
Results
We found total 1701 records in our systematic database search and out of these 17 randomised trials were found eligible for network meta-analysis. For primary prevention of SBP, the odds ratio (95% CrI) for norfloxacin daily was 0.061 (0.0060, 0.33) and for rifaximin daily was 0.037 (0.00085, 0.87) and norfloxacin and rifaximin alternate month was 0.027 (0.00061, 0.61) when compared to placebo or no comparator. For the secondary prevention of SBP, rifaximin daily had odds of 0.022 (0.00011, 0.73).
Conclusion
Rifaximin is useful for both primary and secondary prevention of SBP whereas norfloxacin daily and alternate norfloxacin and rifaximin are useful for primary prophylaxis.</description><identifier>ISSN: 1936-0533</identifier><identifier>EISSN: 1936-0541</identifier><identifier>DOI: 10.1007/s12072-020-10025-1</identifier><identifier>PMID: 32266675</identifier><language>eng</language><publisher>New Delhi: Springer India</publisher><subject>Anti-Bacterial Agents - classification ; Anti-Bacterial Agents - pharmacology ; Antibiotics ; Ascites ; Ascites - drug therapy ; Ascites - etiology ; Bayesian analysis ; Clinical trials ; Colorectal Surgery ; Data bases ; Hepatology ; Humans ; Liver Cirrhosis - complications ; Medicine ; Medicine & Public Health ; Meta-analysis ; Norfloxacin ; Original Article ; Patient Selection ; Peritoneum ; Peritonitis ; Peritonitis - etiology ; Peritonitis - microbiology ; Peritonitis - prevention & control ; Prevention ; Prophylaxis ; Randomization ; Secondary Prevention - methods ; Surgery ; Systematic review ; Treatment Outcome</subject><ispartof>Hepatology international, 2020-05, Vol.14 (3), p.399-413</ispartof><rights>Asian Pacific Association for the Study of the Liver 2020</rights><rights>Asian Pacific Association for the Study of the Liver 2020.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c441t-4e96d04f0d0d8e5518dc66fe1d3f47f298bc85dcdb593366fb2159936d02d8db3</citedby><cites>FETCH-LOGICAL-c441t-4e96d04f0d0d8e5518dc66fe1d3f47f298bc85dcdb593366fb2159936d02d8db3</cites><orcidid>0000-0003-2472-3409</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://link.springer.com/content/pdf/10.1007/s12072-020-10025-1$$EPDF$$P50$$Gspringer$$H</linktopdf><linktohtml>$$Uhttps://link.springer.com/10.1007/s12072-020-10025-1$$EHTML$$P50$$Gspringer$$H</linktohtml><link.rule.ids>314,780,784,27924,27925,41488,42557,51319</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/32266675$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Soni, Hariom</creatorcontrib><creatorcontrib>Kumar-M, Praveen</creatorcontrib><creatorcontrib>Sharma, Vishal</creatorcontrib><creatorcontrib>Bellam, Balaji L.</creatorcontrib><creatorcontrib>Mishra, Shubhra</creatorcontrib><creatorcontrib>Mahendru, Dhruv</creatorcontrib><creatorcontrib>Mandavdhare, Harshal S.</creatorcontrib><creatorcontrib>Medhi, Bikash</creatorcontrib><creatorcontrib>Dutta, Usha</creatorcontrib><creatorcontrib>Singh, Virendra</creatorcontrib><title>Antibiotics for prophylaxis of spontaneous bacterial peritonitis: systematic review & Bayesian network meta-analysis</title><title>Hepatology international</title><addtitle>Hepatol Int</addtitle><addtitle>Hepatol Int</addtitle><description>Background
Various antibiotic regimens are used for primary and secondary prevention of spontaneous bacterial peritonitis (SBP). A systematic review and network meta-analysis to compare various antibiotics regimens for primary and secondary prevention of SBP were done.
Methods
We did a comprehensive literature search using various databases (i.e. MEDLINE via Ovid and PubMed, Embase, Cochrane Central Register of Controlled Trials and others) from inception to 26th October 2019 using various keywords. Only randomised studies which evaluated the role of antibiotics in adult cirrhotic patients with ascites for primary or secondary prophylaxis of SBP were included. The primary outcome was occurrence/recurrence of SBP episode and other outcomes assessed were extra-peritoneal infections and reduction in mortality. We did random-effects network meta-analysis using a Bayesian approach, and calculated odds ratios (ORs) and 95% credible intervals (CrI); agents were ranked using rank probabilities.
Results
We found total 1701 records in our systematic database search and out of these 17 randomised trials were found eligible for network meta-analysis. For primary prevention of SBP, the odds ratio (95% CrI) for norfloxacin daily was 0.061 (0.0060, 0.33) and for rifaximin daily was 0.037 (0.00085, 0.87) and norfloxacin and rifaximin alternate month was 0.027 (0.00061, 0.61) when compared to placebo or no comparator. For the secondary prevention of SBP, rifaximin daily had odds of 0.022 (0.00011, 0.73).
Conclusion
Rifaximin is useful for both primary and secondary prevention of SBP whereas norfloxacin daily and alternate norfloxacin and rifaximin are useful for primary prophylaxis.</description><subject>Anti-Bacterial Agents - classification</subject><subject>Anti-Bacterial Agents - pharmacology</subject><subject>Antibiotics</subject><subject>Ascites</subject><subject>Ascites - drug therapy</subject><subject>Ascites - etiology</subject><subject>Bayesian analysis</subject><subject>Clinical trials</subject><subject>Colorectal Surgery</subject><subject>Data bases</subject><subject>Hepatology</subject><subject>Humans</subject><subject>Liver Cirrhosis - complications</subject><subject>Medicine</subject><subject>Medicine & Public Health</subject><subject>Meta-analysis</subject><subject>Norfloxacin</subject><subject>Original Article</subject><subject>Patient Selection</subject><subject>Peritoneum</subject><subject>Peritonitis</subject><subject>Peritonitis - etiology</subject><subject>Peritonitis - microbiology</subject><subject>Peritonitis - prevention & control</subject><subject>Prevention</subject><subject>Prophylaxis</subject><subject>Randomization</subject><subject>Secondary Prevention - methods</subject><subject>Surgery</subject><subject>Systematic review</subject><subject>Treatment Outcome</subject><issn>1936-0533</issn><issn>1936-0541</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2020</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp9kctu1jAQhS1ERW-8AIvKEhJiE_A9SXdtRQGpEhtYW048AZckTj3-KXl7TFNaiUVXY2u-OePjQ8grzt5xxur3yAWrRcUEq8pd6Io_Iwe8laZiWvHnD2cp98kh4jVjWhtuXpB9KYQxptYHJJ_NOXQh5tAjHWKiS4rLj3V0vwPSOFBc4pzdDHGHtHN9hhTcSJdScpxDDnhKccUMkysKNMGvALf0DT13K2BwM50h38b0k06QXeVmN64Y8JjsDW5EeHlfj8i3yw9fLz5VV18-fr44u6p6pXiuFLTGMzUwz3wDWvPG98YMwL0cVD2Itun6Rvved7qVsnQ6wXVbPHsmfOM7eUTebrrF1M0OMNspYA_juBmyQja10UwpVdDX_6HXcZfKewulyt8yXchCiY3qU0RMMNglhcml1XJm_2Zit0xsycTeZWJ5GTq5l951E_iHkX8hFEBuAJbW_B3S4-4nZP8AaBCY-A</recordid><startdate>20200501</startdate><enddate>20200501</enddate><creator>Soni, Hariom</creator><creator>Kumar-M, Praveen</creator><creator>Sharma, Vishal</creator><creator>Bellam, Balaji L.</creator><creator>Mishra, Shubhra</creator><creator>Mahendru, Dhruv</creator><creator>Mandavdhare, Harshal S.</creator><creator>Medhi, Bikash</creator><creator>Dutta, Usha</creator><creator>Singh, Virendra</creator><general>Springer India</general><general>Springer Nature B.V</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7U7</scope><scope>C1K</scope><scope>K9.</scope><scope>NAPCQ</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0003-2472-3409</orcidid></search><sort><creationdate>20200501</creationdate><title>Antibiotics for prophylaxis of spontaneous bacterial peritonitis: systematic review & Bayesian network meta-analysis</title><author>Soni, Hariom ; Kumar-M, Praveen ; Sharma, Vishal ; Bellam, Balaji L. ; Mishra, Shubhra ; Mahendru, Dhruv ; Mandavdhare, Harshal S. ; Medhi, Bikash ; Dutta, Usha ; Singh, Virendra</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c441t-4e96d04f0d0d8e5518dc66fe1d3f47f298bc85dcdb593366fb2159936d02d8db3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2020</creationdate><topic>Anti-Bacterial Agents - classification</topic><topic>Anti-Bacterial Agents - pharmacology</topic><topic>Antibiotics</topic><topic>Ascites</topic><topic>Ascites - drug therapy</topic><topic>Ascites - etiology</topic><topic>Bayesian analysis</topic><topic>Clinical trials</topic><topic>Colorectal Surgery</topic><topic>Data bases</topic><topic>Hepatology</topic><topic>Humans</topic><topic>Liver Cirrhosis - complications</topic><topic>Medicine</topic><topic>Medicine & Public Health</topic><topic>Meta-analysis</topic><topic>Norfloxacin</topic><topic>Original Article</topic><topic>Patient Selection</topic><topic>Peritoneum</topic><topic>Peritonitis</topic><topic>Peritonitis - etiology</topic><topic>Peritonitis - microbiology</topic><topic>Peritonitis - prevention & control</topic><topic>Prevention</topic><topic>Prophylaxis</topic><topic>Randomization</topic><topic>Secondary Prevention - methods</topic><topic>Surgery</topic><topic>Systematic review</topic><topic>Treatment Outcome</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Soni, Hariom</creatorcontrib><creatorcontrib>Kumar-M, Praveen</creatorcontrib><creatorcontrib>Sharma, Vishal</creatorcontrib><creatorcontrib>Bellam, Balaji L.</creatorcontrib><creatorcontrib>Mishra, Shubhra</creatorcontrib><creatorcontrib>Mahendru, Dhruv</creatorcontrib><creatorcontrib>Mandavdhare, Harshal S.</creatorcontrib><creatorcontrib>Medhi, Bikash</creatorcontrib><creatorcontrib>Dutta, Usha</creatorcontrib><creatorcontrib>Singh, Virendra</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Toxicology Abstracts</collection><collection>Environmental Sciences and Pollution Management</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Nursing & Allied Health Premium</collection><collection>MEDLINE - Academic</collection><jtitle>Hepatology international</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Soni, Hariom</au><au>Kumar-M, Praveen</au><au>Sharma, Vishal</au><au>Bellam, Balaji L.</au><au>Mishra, Shubhra</au><au>Mahendru, Dhruv</au><au>Mandavdhare, Harshal S.</au><au>Medhi, Bikash</au><au>Dutta, Usha</au><au>Singh, Virendra</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Antibiotics for prophylaxis of spontaneous bacterial peritonitis: systematic review & Bayesian network meta-analysis</atitle><jtitle>Hepatology international</jtitle><stitle>Hepatol Int</stitle><addtitle>Hepatol Int</addtitle><date>2020-05-01</date><risdate>2020</risdate><volume>14</volume><issue>3</issue><spage>399</spage><epage>413</epage><pages>399-413</pages><issn>1936-0533</issn><eissn>1936-0541</eissn><abstract>Background
Various antibiotic regimens are used for primary and secondary prevention of spontaneous bacterial peritonitis (SBP). A systematic review and network meta-analysis to compare various antibiotics regimens for primary and secondary prevention of SBP were done.
Methods
We did a comprehensive literature search using various databases (i.e. MEDLINE via Ovid and PubMed, Embase, Cochrane Central Register of Controlled Trials and others) from inception to 26th October 2019 using various keywords. Only randomised studies which evaluated the role of antibiotics in adult cirrhotic patients with ascites for primary or secondary prophylaxis of SBP were included. The primary outcome was occurrence/recurrence of SBP episode and other outcomes assessed were extra-peritoneal infections and reduction in mortality. We did random-effects network meta-analysis using a Bayesian approach, and calculated odds ratios (ORs) and 95% credible intervals (CrI); agents were ranked using rank probabilities.
Results
We found total 1701 records in our systematic database search and out of these 17 randomised trials were found eligible for network meta-analysis. For primary prevention of SBP, the odds ratio (95% CrI) for norfloxacin daily was 0.061 (0.0060, 0.33) and for rifaximin daily was 0.037 (0.00085, 0.87) and norfloxacin and rifaximin alternate month was 0.027 (0.00061, 0.61) when compared to placebo or no comparator. For the secondary prevention of SBP, rifaximin daily had odds of 0.022 (0.00011, 0.73).
Conclusion
Rifaximin is useful for both primary and secondary prevention of SBP whereas norfloxacin daily and alternate norfloxacin and rifaximin are useful for primary prophylaxis.</abstract><cop>New Delhi</cop><pub>Springer India</pub><pmid>32266675</pmid><doi>10.1007/s12072-020-10025-1</doi><tpages>15</tpages><orcidid>https://orcid.org/0000-0003-2472-3409</orcidid></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1936-0533 |
| ispartof | Hepatology international, 2020-05, Vol.14 (3), p.399-413 |
| issn | 1936-0533 1936-0541 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_2387650444 |
| source | MEDLINE; SpringerLink Journals |
| subjects | Anti-Bacterial Agents - classification Anti-Bacterial Agents - pharmacology Antibiotics Ascites Ascites - drug therapy Ascites - etiology Bayesian analysis Clinical trials Colorectal Surgery Data bases Hepatology Humans Liver Cirrhosis - complications Medicine Medicine & Public Health Meta-analysis Norfloxacin Original Article Patient Selection Peritoneum Peritonitis Peritonitis - etiology Peritonitis - microbiology Peritonitis - prevention & control Prevention Prophylaxis Randomization Secondary Prevention - methods Surgery Systematic review Treatment Outcome |
| title | Antibiotics for prophylaxis of spontaneous bacterial peritonitis: systematic review & Bayesian network meta-analysis |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-24T02%3A44%3A46IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Antibiotics%20for%20prophylaxis%20of%20spontaneous%20bacterial%20peritonitis:%20systematic%20review%20&%20Bayesian%20network%20meta-analysis&rft.jtitle=Hepatology%20international&rft.au=Soni,%20Hariom&rft.date=2020-05-01&rft.volume=14&rft.issue=3&rft.spage=399&rft.epage=413&rft.pages=399-413&rft.issn=1936-0533&rft.eissn=1936-0541&rft_id=info:doi/10.1007/s12072-020-10025-1&rft_dat=%3Cproquest_cross%3E2387650444%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2402505765&rft_id=info:pmid/32266675&rfr_iscdi=true |